Clovis' Rociletinib Facing Three-Year Delay If FDA Follows Panel's Lead
This article was originally published in The Pink Sheet Daily
Lung cancer drug gets thumbs down for accelerated approval from advisory committee, meaning FDA's thumbs up might have to wait for results from 900-patient confirmatory trial, which some panelists said should be redesigned to provide more clarity around dosing.
You may also be interested in...
Modeling can better inform candidate and dose selection, and support novel endpoints, labeling and postmarketing safety, even though it means stepping off the beaten path for drug development, participants say at US FDA's inaugural workshop on model-informed drug development under PDUFA VI.
US FDA received 110 designation requests in July, a high mark that reflects the 60 days needed to review such requests ahead of the 30 September statutory expiration; agency is allowing email submission of RPD and orphan drug designation requests during the COVID-19 pandemic and expects to roll out an online portal for orphan designation requests later this year.
Most vaccines will be distributed centrally by McKesson, but those with ultra-cold storage requirements will be shipped directly from the manufacturer to the vaccination site. Data exchange system will enable public and private databases to talk to each other and help ensure individuals receive timely revaccination with a second dose of the same vaccine regardless of location.